Page 214 - 2019_07 resto del Mondo-web

A.S. Macwan et al. References
1. Offermanns S. Activation of platelet func- tion through G protein-coupled receptors. Circ Res. 2006;99(12):1293-1304.
2. Brass LF, Wannemacher KM, Ma P, Stalker TJ. Regulating thrombus growth and stabili- ty to achieve an optimal response to injury. J Thromb Haemost. 2011;9 (Suppl 1):66-75.
3. Brass LF, Diamond SL, Stalker TJ. Platelets and hemostasis: a new perspective on an old subject. Blood Adv. 2016;1(1):5-9.
4. Welsh JD, Stalker TJ, Voronov R, et al. A sys- tems approach to hemostasis: 1. The inter- dependence of thrombus architecture and agonist movements in the gaps between platelets. Blood. 2014;124(11):1808-1815.
5. Stalker TJ, Welsh JD, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood. 2014;124(11): 1824-1831.
6. Chandrasekaran A, Ellett F, Jorgensen J, Irimia D. Temporal gradients limit the accu- mulation of neutrophils towards sources of chemoattractant. Microsyst Nanoeng. 2017;3.
7. Petrie Aronin CE, Zhao YM, Yoon JS, et al. Migrating myeloid cells sense temporal dynamics of chemoattractant concentra- tions. Immunity. 2017;47(5):862-874.e863.
8. Lin F, Butcher EC. Modeling the role of homologous receptor desensitization in cell gradient sensing. J Immunol. 2008;181(12): 8335-8343.
9. Shankaran H, Wiley HS, Resat H. Receptor downregulation and desensitization enhance the information processing ability of signalling receptors. BMC Syst Biol. 2007;1:48.
10. Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet- signaling network. Blood. 2013;121(10): 1875-1885.
11. Baurand A, Eckly A, Bari N, et al. Desensitization of the platelet aggregation response to ADP: differential down-regula- tion of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000;84(3):484-491.
12. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005;105(9):3552-3560.
13. Murray R, FitzGerald GA. Regulation of thromboxane receptor activation in human platelets. Proc Natl Acad Sci U S A. 1989;86(1):124-128.
14. Janes SL, Wilson DJ, Cox AD, Chronos NA, Goodall AH. ADP causes partial degranula- tion of platelets in the absence of aggrega- tion. Br J Haematol. 1994;86(3):568-573.
15. Rand ML, Perry DW, Packham MA, Gemmell CH, Yeo EL, Kinlough-Rathbone
RL. Conditions influencing release of gran- ule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta- thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol. 1996;52(4):288-294.
16. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood. 1993;82(2): 505-512.
17. Hammes SR, Shapiro MJ, Coughlin SR. Shutoff and agonist-triggered internalization of protease-activated receptor 1 can be sep- arated by mutation of putative phosphoryla- tion sites in the cytoplasmic tail. Biochemistry. 1999;38(29):9308-9316.
18. Lazari MF, Liu X, Nakamura K, Benovic JL, Ascoli M. Role of G protein-coupled recep- tor kinases on the agonist-induced phospho- rylation and internalization of the follitropin receptor. Mol Endocrinol. 1999;13(6):866- 878.
19. Krupnick JG, Benovic JL. The role of recep- tor kinases and arrestins in G protein-cou- pled receptor regulation. Annu Rev Pharmacol Toxicol. 1998;38:289-319.
Protease-activated receptor 1 (PAR1) sig- nalling desensitization is counteracted via PAR4 signalling in human platelets. Biochem J. 2011;436(2):469-480.
27. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activa- tion by thrombin. J Biol Chem. 2000;275(33):25216-25221.
28. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413(6851):74-78.
29. Trejo J, Hammes SR, Coughlin SR. Termination of signaling by protease-acti- vated receptor-1 is linked to lysosomal sort- ing. Proc Natl Acad Sci U S A. 1998;95(23):13698-13702.
30. Cooper DM, Rodbell M. ADP is a potent inhibitor of human platelet plasma mem- brane adenylate cyclase. Nature. 1979;282 (5738):517-518.
31. Riedl J, Kaider A, Marosi C, et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous throm- boembolism and poor prognosis. Thromb Haemost. 2017;117(1):90-98.
32. Boneu B, Bugat R, Boneu A, Eche N, Sie P, Combes PF. Exhausted platelets in patients with malignant solid tumors without evi- dence of active consumption coagulopathy. Eur J Cancer Clin Oncol. 1984;20(7):899-
20. Claing A, Laporte SA, Caron MG, Lefkowitz
RJ. Endocytosis of G protein-coupled recep-
tors: roles of G protein-coupled receptor
kinases and beta-arrestin proteins. Prog 903.
Neurobiol. 2002;66(2):61-79.
21. Jones CI, Sage T, Moraes LA, et al. Platelet
endothelial cell adhesion molecule-1 inhibits platelet response to thrombin and von Willebrand factor by regulating the internal- ization of glycoprotein Ib via AKT/glycogen synthase kinase-3/dynamin and integrin alphaIIbbeta3. Arterioscler Thromb Vasc Biol. 2014;34(9):1968-1976.
22. Doppler H, Storz P. Regulation of VASP by phosphorylation: consequences for cell migration. Cell Adh Migr. 2013;7(6):482- 486.
23. Gerits N, Mikalsen T, Kostenko S, Shiryaev A, Johannessen M, Moens U. Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-acti- vated protein kinase 5 and requires PKA- induced nuclear export of MK5. J Biol Chem. 2007;282(51):37232-37243.
24. Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphopro- tein regulates its interaction with actin. J Biol Chem. 2000;275(40):30817-30825.
25. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107- 144.
26. Falker K, Haglund L, Gunnarsson P, Nylander M, Lindahl TL, Grenegard M.
33. Fondu P. Exhausted platelets in cancer and other conditions. Eur J Cancer Clin Oncol. 1985;21(3):277-282.
34. Lundahl TH, Petersson J, Fagerberg IH, Berg S, Lindahl TL. Impaired platelet function correlates with multi-organ dysfunction. A study of patients with sepsis. Platelets. 1998;9(3-4):223-225.
35. Lundahl TH, Lindahl TL, Fagerberg IH, Egberg N, Bunescu A, Larsson A. Activated platelets and impaired platelet function in intensive care patients analyzed by flow cytometry. Blood Coagul Fibrinolysis. 1996;7(2):218-220.
36. Nenci GG, Berrettini M, Todisco T, Costantini V, Grasselli S. Exhausted platelets in chronic obstructive pulmonary disease. Respiration. 1983;44(1):71-76.
37. Fong JS, Kaplan BS. Impairment of platelet aggregation in hemolytic uremic syndrome: evidence for platelet "exhaustion". Blood. 1982;60(3):564-570.
38. Welsh JD, Colace TV, Muthard RW, Stalker TJ, Brass LF, Diamond SL. Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse. J Thromb Haemost. 2012;10(11):2344-2353.
39. Zhang W, Colman RW. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/ activation of phosphodiesterase 3A. Blood. 2007;110(5):1475-1482.
1492
haematologica | 2019; 104(7)